Silencing RBBP6 (Retinoblastoma Binding Protein 6) sensitises breast cancer cells MCF7 to staurosporine and camptothecin-induced cell death

Immunobiology

Volumn 219, Issue 8, 2014, Pages 593-601

  Moela, Pontsho ^a   Choene, Mpho M S ^a   Motadi, Lesetja R ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Apoptosis; Camptothecin; Retinoblastoma binding protein 6; RNA interference; Staurosporine

Indexed keywords

CAMPTOTHECIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN; SMALL INTERFERING RNA; STAUROSPORINE; UBIQUITIN PROTEIN LIGASE E3; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DNA BINDING PROTEIN; RBBP6 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TISSUE CULTURE; WESTERN BLOTTING; BREAST NEOPLASMS; DOWN REGULATION; DRUG EFFECTS; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CARRIER PROTEINS; CELL GROWTH PROCESSES; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE SILENCING; HUMANS; MCF-7 CELLS; RNA, SMALL INTERFERING; STAUROSPORINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902115699     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.03.002     Document Type: Article

References (18)

1. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Del. Rev. 2007, 59:75-86.
2. Arakawa Y., Saito S., Yamada H., Aiba H. Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-XL and promotes apoptosis of MCF-7 breast cancer cells. Apoptosis 2009, 14:1076-1085.
3. Bai L., Zhu W.G. p53 structure, function and therapeutic applications. J. Cancer Mol. 2006, 2(4):141-153.
4. Li G., Bush J.A., Ho V.C. p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J. Invest. Dermatol. 2000, 115:514-519.
5. Malloy K.L., Choi H., Fiorilla C., Matainaho V.T., Gerwick W.H. Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction. Bioorg. Med. Chem. Lett. 2012, 22:683-688.
6. Morissette M.C., Vachon-Beaudoin G., Parent J., Chakir J., Milot J. Increased p53 Level, Bax/Bcl-xL Ratio, and TRAIL Receptor Expression in Human Emphysema 2007, 10.1164/rccm.200710-1486OC.
7. Motadi L.R., Bhoola K.D., Dlamini Z. Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer. Immunobiology 2011, 216:1065-1073.
8. Motadi L.R., Misso N.L., Dlamini Z., Bhoola K.D. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets. Int. Immunopharmacol. 2007, 7:1934-1947.
9. Ntwasa M. Retinoblastoma binding protein 6 is a potential target for therapeutic drugs. Biotechnol. Mol. Biol. 2008, 3(2):24-31.
10. Porichi O., Nikolaidou M.E., Apostolaki A., Tserkezoglou A., Arnogiannaki N., Kassanos D., Margaritis L., Panotopoulou E. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. Anticancer Res. 2009, 29(10):3977-3982.
11. Pugh D.J.R., Eiso A.B., Faro A., Lutya P.T., Hoffmann E., Rees D.J.G. DWNN, a novel ubiquitin-like domain, implicates RBBP6 IN Mrna processing and ubiquitin-like pathways. BMC Struct. Biol. 2006, 6:1.
12. Pretorius A., Kaur M., Wamalwa M., February M.F. Functional analysis and characterization of the human RBBP6 promoters based on a combination of molecular biology and in silico approaches provide additional evidence for RBBP6 role in apoptosis. JBio 2013, 1(1):2251-3159.
13. Shangary S., Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 2008, 14(17):5318-5324.
14. Shen Y., White E. P53-dependent apoptosis pathways. Adv. Cancer Res. 2001, 82:58-84.
15. Vassilev L.T., Vu B.T., Graves B., et al. In Vivo activation of the p53 pathway by small molecule antagonists of MDM2. Science 2003, 343:844-848.
16. Xue L., Chiu S., Oleinick N.L. Staurosporine-induced death of MCF-7 human breast cancer cells: a distinction between caspase-3-dependent steps of apoptosis and the critical lethal lessions. Exp. Cell Res. 2003, 283:135-145.
17. Zhang Z.W., Patchett S.E., Farthing M.J.G. Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity. Anticancer Drugs 2000, 11(9):757-764.
18. Zeng C.W., Zhang X.J., Lin K.Y., Ye H., Feng S.Y., Zhang H., Chen Y.Q. Camptothecin induces apoptosis in cancer cells via miR-125b mediated mitochondrial pathways. Mol. Pharmacol. 2012.